TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01908491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion
Description: Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15\~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
Study: NCT02218697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influsplit™ Tetra (Fluarix™ Tetra)
Description: Intramuscular injection, 1 dose each in Control and Co-Ad groups.
Study: NCT03789318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 0.02 mg/kg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 0.02 mg/kg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 0.02 mg/kg IV administered intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: 0.02 mg/kg IV administered intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: 0.02 mg/kg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg IV administered intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg IV administered intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg IV administered intraoperatively
Study: NCT02218697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influsplit™ Tetra (Fluarix™ Tetra)
Description: Intramuscular injection, 1 dose each in Control and Co-Ad groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax™ 23
Description: Intramuscular injection, 1 dose each in Control and Co-Ad groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax™ 23
Description: Intramuscular injection, 1 dose each in Control and Co-Ad groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Saline)
Description: Intramuscular injection, 1 dose each in Control and Co-Ad groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Saline)
Description: Intramuscular injection, 1 dose each in Control and Co-Ad groups.
Study: NCT03430024

Intervention type: OTHER
Intervention: Association of Myosin VI with oestrogen receptor
Description: 1. Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~2. Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~3. Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues.

Intervention type: OTHER
Intervention: Association of Myosin VI with oestrogen receptor
Description: 1. Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~2. Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~3. Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues.
Study: NCT03734016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Ibrutinib 420 mg orally once daily
Study: NCT03220724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF
Description: Administered by intramuscular (IM) injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF
Description: Administered by intramuscular (IM) injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF
Description: Administered by intramuscular (IM) injection in the thigh
Study: NCT00295009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProDisc
Description: Total disc replacement with ProDisc

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProDisc
Description: Total disc replacement with ProDisc

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProDisc
Description: Total disc replacement with ProDisc

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProDisc
Description: Total disc replacement with ProDisc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Fusion
Description: A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Fusion
Description: A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
Study: NCT02147730

Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: all patients receiving a regional anesthesia/analgesia technique

Intervention type: PROCEDURE
Intervention: non-regional anesthesia
Description: all patients receiving other-than-regional anesthesia techniques
Study: NCT02844244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training group
Description: The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
Study: NCT03981094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: capsule
Study: NCT03789318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg IV administered intraoperatively
Study: NCT01533337

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Free dorsal digital flap
Description: The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
Study: NCT01266252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed.
Study: NCT00353808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Study: NCT04190407

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intravenous access
Description: A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
Study: NCT00726791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
Study: NCT03789318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg IV administered intraoperatively
Study: NCT00079391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
Study: NCT03223922

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiation therapy
Description: Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
Study: NCT03478254

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year.

Intervention type: BIOLOGICAL
Intervention: Pneumococcal vaccination
Description: Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~* One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~* One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~* One PPSV 23 dose in the last 5 years.~* One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year.

Intervention type: BIOLOGICAL
Intervention: Hepatitis B Virus (HBV) vaccination
Description: Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months.
Study: NCT02720055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological workbook

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic information workbook
Description: Basic rehabilitation information that represents current practice.
Study: NCT04926610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proactive clinical ethics consultation
Description: When the patients meet the initiation criteria of this study, the patients were randomly assigned to the intervention group (providing proactive clinical ethics consultation) and the routine care group (no proactive clinical ethics consultation) after obtaining the consent of the subjects.
Study: NCT02066831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedical coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedical coaching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Study: NCT02664311

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Ventilation
Description: Patients are randomized to receive either jet or conventional ventilation during this study

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional ventilation
Description: Conventional ventilator - control arm
Study: NCT03220724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF
Description: Administered by intramuscular (IM) injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF
Description: Administered by intramuscular (IM) injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF
Description: Administered by intramuscular (IM) injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505w53
Description: Administered by IM injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505w53
Description: Administered by IM injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505w53
Description: Administered by IM injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505w78
Description: Administered by IM injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505w78
Description: Administered by IM injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505w78
Description: Administered by IM injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 M5
Description: Administered by IM injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Admixed with all CH505 gp120 proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Admixed with all CH505 gp120 proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Admixed with all CH505 gp120 proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Admixed with all CH505 gp120 proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Admixed with all CH505 gp120 proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Admixed with all CH505 gp120 proteins

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection in the thigh

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection in the thigh
Study: NCT02803749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02358005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy 60mj
Study: NCT03789318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg IV administered intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5-10 mg PO administered post-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5-10 mg PO administered post-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5-10 mg PO administered post-surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5-10 mg PO administered post-surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5-10 mg PO administered post-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008 10 mg
Description: 10 mg CA-008 reconstituted in saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008 15 mg
Description: 15 mg CA-008 reconstituted in saline.
Study: NCT01847794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cell Search® CTC epithelial kit
Description: Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study: NCT00700661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (unspecified)
Description: Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
Study: NCT03744611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CE
Description: 550mg capsule (Eucommia ulmoides Oliver extract)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 550mg capsule (Placebo)
Study: NCT00674700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 IR house dust mites allergen extract tablet
Description: One sublingual tablet daily for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 IR house dust mites allergen extract tablet
Description: One sublingual tablet daily for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: One sublingual tablet daily for one year
Study: NCT02049281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Description: Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
Study: NCT01543698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Study: NCT03983850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.
Study: NCT01543698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Study: NCT02945683

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reuterin D3
Description: Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sunflower oil, medium chain triglycerides, silicon dioxide
Study: NCT02823431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain aqueous gel
Study: NCT00569569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: juxtascleral depot injection of Retaane
Description: juxtascleral depot injection of Retaane
Study: NCT00634894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femara
Description: 2.5 mg by mouth daily x 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule by mouth daily x 12 weeks
Study: NCT01220375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine, G-CSF, & Plerixafor
Description: Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine and Plerixafor
Description: Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF and Plerixafor
Description: Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood
Description: Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.